Reza Vaezeafshar, MD
Otolaryngology · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 1 carrier
- Offices
- 2
Offices
2 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Alta Bates Summit Medical Center - Alta Bates Camp · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vaezeafshar’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A144953 · Current
Licensed to practise in California · since 2016 · expires 2028-09-30 · Tehran University of Medical Sciences and Health Services.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Alta Bates Summit Medical Center - Alta Bates CampBerkeley, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.298, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Alta Bates Summit Medical Center - Alta Bates Camp
Behind the star rating — Deaths: 2 better, 5 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 6 the same, 1 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.298 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.18 (0.16 to 2.2) · 730 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.51 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 188.12 (132.31 to 243.94) · 50 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 50 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.4 · 189 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.6 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 103 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,585 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.4) · 3,929 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.11 to 0.51) · 3,954 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.15 (0.95 to 5.36) · 754 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0 to 3.33) · 325 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.99 (0.39 to 3.59) · 717 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.85 (2.27 to 19.44) · 326 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.08 to 8.49) · 302 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.68 (0.19 to 3.18) · 184 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.17 (0 to 0.88) · 3,240 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.207 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.48 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.785 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.4 · 243 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -58.2 · 194 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -12.3 · 177 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 209 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.8 to 7.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.2 (9.4 to 15.5) · 215 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.8 · 150 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 81 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (10 to 18.1) · 315 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1.2) · 137 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 15% of those asked)
| Cleanliness | 2 |
| Nurse communication | 2 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 2 |
| Overall hospital rating | 2 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 72% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 73% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 58% |
| Staff "always" explained new medications | 67% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 49% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 38% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$120,001
Medicare paid this office $120,001 for 533 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 300 | $44,156 | $96 |
| Short return visit (20+ min) | 195 | $16,757 | $59 |
| New patient visit (45+ min) | 130 | $15,106 | $116 |
| Diagnostic exam of nasal passages using an endoscope | 111 | $9,072 | $64 |
| New patient visit (30+ min) | 127 | $8,336 | $66 |
See all 11 services
| Return visit (30+ min) | 300 | $44,156 | $96 |
| Short return visit (20+ min) | 195 | $16,757 | $59 |
| New patient visit (45+ min) | 130 | $15,106 | $116 |
| Diagnostic exam of nasal passages using an endoscope | 111 | $9,072 | $64 |
| New patient visit (30+ min) | 127 | $8,336 | $66 |
| Diagnostic exam of voice box using a flexible endoscope | 101 | $7,897 | $70 |
| Removal of impacted ear wax | 168 | $5,705 | $27 |
| Long return visit (40+ min) | 17 | $2,361 | $139 |
| New patient visit (60+ min) | 12 | $1,978 | $165 |
| Simple control of nose bleed | 12 | $409 | $31 |
| Exam of ear using a microscope | 24 | $267 | $8 |
Who their Medicare patients are
533 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 14% · Women 60% · Also on Medicaid 16% · Health risk score 1.05. At or below the middle of the specialty; the typical otolaryngology clinician is at 1.19.
Conditions among them: High blood pressure 64% · Chronic kidney disease 21% · Diabetes 20% · Coronary heart disease 19% · Depression 18% · Cancer 14% · Atrial fibrillation 14% · Heart failure 9% · Stroke 9% · COPD 8% · Dementia 5%.
The office billed $441,595, Medicare allowed $158,116 and paid $120,001; for 1,612 services of 41 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 533 | 1,612 | 76 | 1.05 | $441,595 | $120,001 |
| 2023 | 240 | 639 | 77 | 1.03 | $260,472 | $69,634 |
| 2022 | 366 | 853 | 76 | 1.08 | $295,813 | $75,672 |
| 2021 | 399 | 1,267 | 74 | 1.10 | $269,772 | $71,356 |
| 2020 | 330 | 813 | 75 | 1.23 | $183,835 | $45,637 |
| 2019 | 129 | 296 | 76 | 1.08 | $86,356 | $29,524 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Short return visit (20+ min) | 113 | $15,919 | $79 |
| Return visit (30+ min) | 102 | $15,547 | $115 |
| Diagnostic exam of nasal passages using an endoscope | 43 | $11,313 | $198 |
| Diagnostic exam of voice box using a flexible endoscope | 51 | $8,190 | $130 |
| New patient visit (45+ min) | 43 | $6,295 | $146 |
| New patient visit (30+ min) | 65 | $5,823 | $90 |
| Removal of impacted ear wax | 31 | $1,308 | $41 |
2022: 9 services
| Short return visit (20+ min) | 192 | $17,627 | $65 |
| Diagnostic exam of nasal passages using an endoscope | 67 | $11,988 | $144 |
| New patient visit (30+ min) | 121 | $10,743 | $89 |
| New patient visit (45+ min) | 60 | $8,571 | $143 |
| Diagnostic exam of voice box using a flexible endoscope | 67 | $8,505 | $113 |
| Return visit (30+ min) | 69 | $8,216 | $108 |
| Removal of impacted ear wax | 67 | $2,549 | $38 |
| Short return visit | 17 | $540 | $30 |
| Exam of ear using a microscope | 29 | $523 | $16 |
2021: 9 services
| Short return visit (20+ min) | 266 | $26,672 | $56 |
| New patient visit (30+ min) | 156 | $10,583 | $68 |
| New patient visit (45+ min) | 74 | $9,141 | $124 |
| Return visit (30+ min) | 65 | $6,388 | $86 |
| Diagnostic exam of voice box using a flexible endoscope | 91 | $6,197 | $54 |
| Diagnostic exam of nasal passages using an endoscope | 96 | $3,268 | $25 |
| Short return visit | 78 | $2,523 | $30 |
| Removal of impacted ear wax | 58 | $1,519 | $24 |
| Exam of ear using a microscope | 48 | $391 | $8 |
2020: 10 services
| New patient visit (30+ min) | 149 | $9,443 | $63 |
| Short return visit (20+ min) | 148 | $8,830 | $44 |
| Diagnostic exam of voice box using a flexible endoscope | 73 | $6,015 | $72 |
| Return visit (30+ min) | 62 | $5,374 | $74 |
| Diagnostic exam of nasal passages using an endoscope | 42 | $4,229 | $81 |
| New patient visit (45+ min) | 27 | $2,898 | $107 |
| Short return visit | 58 | $1,907 | $27 |
| Removal of impacted ear wax | 65 | $1,660 | $26 |
| New patient visit (15+ min) | 25 | $1,155 | $46 |
| Exam of ear using a microscope | 16 | $398 | $17 |
2019: 7 services
| Short return visit (20+ min) | 85 | $7,238 | $69 |
| Diagnostic exam of nasal passages using an endoscope | 21 | $6,035 | $201 |
| New patient visit (30+ min) | 35 | $3,244 | $93 |
| Return visit (30+ min) | 22 | $2,434 | $101 |
| Diagnostic exam of voice box using a flexible endoscope | 20 | $2,393 | $114 |
| Removal of impacted ear wax | 22 | $970 | $42 |
| Exam of ear using a microscope | 15 | $591 | $30 |
Drugs they prescribed that Part D paid
$12,851
Pharmacies billed $12,851 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
483 generic and 12 brand-name prescriptions · $12,851 in drug cost · 53 antibiotic prescriptions to 43 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ipratropium | 70 | $2,617 | $37 |
| Azelastine | 97 | $2,494 | $26 |
| Ciprofloxacin-Dexamethasone | 19 | $2,071 | $109 |
| Ofloxacin | 20 | $785 | $39 |
| Fluocinolone Acetonide Oil | 14 | $497 | $35 |
See all 14 drugs
| Ipratropium | 70 | $2,617 | $37 |
| Azelastine | 97 | $2,494 | $26 |
| Ciprofloxacin-Dexamethasone | 19 | $2,071 | $109 |
| Ofloxacin | 20 | $785 | $39 |
| Fluocinolone Acetonide Oil | 14 | $497 | $35 |
| Dexamethasone | 17 | $449 | $26 |
| Amoxicillin-Clavulanate Potass | 36 | $351 | $10 |
| Mupirocin | 38 | $307 | $8 |
| Clotrimazole-Betamethasone | 23 | $257 | $11 |
| Omeprazole | 23 | $181 | $8 |
| Fluticasone Propionate | 11 | $134 | $12 |
| Methylprednisolone | 14 | $105 | $8 |
| Famotidine | 15 | $88 | $6 |
| Prednisone | 20 | $60 | $3 |
Year by year
| 2024 | 495 | 199 | None | 2% | $12,851 |
| 2023 | 237 | 102 | None | None | $7,219 |
| 2022 | 339 | 152 | None | 4% | $13,894 |
| 2021 | 621 | 210 | None | None | $20,458 |
| 2020 | 361 | 153 | None | 5% | $12,540 |
| 2019 | 152 | 74 | None | 8% | $4,930 |
| 2018 | 31 | 29 | 94% (29) | 0% | $165 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Ofloxacin | 20 | $1,381 | $69 |
| Ipratropium | 30 | $890 | $30 |
| Clotrimazole-Betamethasone | 22 | $821 | $37 |
| Azelastine | 12 | $333 | $28 |
| Famotidine | 16 | $200 | $13 |
| Lidocaine Hcl Viscous | 13 | $161 | $12 |
| Mupirocin | 14 | $105 | $8 |
| Amoxicillin-Clavulanate Potass | 14 | $105 | $8 |
2022: 10 drugs
| Ipratropium | 63 | $3,316 | $53 |
| Ciprofloxacin-Dexamethasone | 12 | $2,181 | $182 |
| Azelastine | 36 | $1,928 | $54 |
| Ofloxacin | 21 | $1,661 | $79 |
| Fluticasone Propionate | 41 | $870 | $21 |
| Triamcinolone Acetonide | 14 | $717 | $51 |
| Clotrimazole-Betamethasone | 19 | $474 | $25 |
| Clotrimazole | 11 | $403 | $37 |
| Mupirocin | 21 | $239 | $11 |
| Prednisone | 13 | $37 | $3 |
2021: 12 drugs
| Ipratropium | 134 | $7,527 | $56 |
| Azelastine | 60 | $2,525 | $42 |
| Fluticasone Propionate | 115 | $1,769 | $15 |
| Clotrimazole | 29 | $1,082 | $37 |
| Ofloxacin | 24 | $925 | $39 |
| Omeprazole | 43 | $646 | $15 |
| Famotidine | 41 | $514 | $13 |
| Dexamethasone | 16 | $282 | $18 |
| Mupirocin | 19 | $211 | $11 |
| Clotrimazole-Betamethasone | 19 | $209 | $11 |
| Amoxicillin-Clavulanate Potass | 16 | $178 | $11 |
| Prednisone | 17 | $81 | $5 |
2020: 10 drugs
| Ciprodex | 13 | $3,418 | $263 |
| Ipratropium | 65 | $2,737 | $42 |
| Fluticasone Propionate | 58 | $1,156 | $20 |
| Clotrimazole | 19 | $1,017 | $54 |
| Ofloxacin | 19 | $753 | $40 |
| Azelastine | 20 | $679 | $34 |
| Famotidine | 34 | $349 | $10 |
| Amoxicillin-Clavulanate Potass | 14 | $225 | $16 |
| Mupirocin | 20 | $185 | $9 |
| Omeprazole | 24 | $167 | $7 |
2019: 3 drugs
| Fluticasone Propionate | 35 | $319 | $9 |
| Azelastine | 13 | $274 | $21 |
| Amoxicillin-Clavulanate Potass | 11 | $104 | $9 |
2018: 2 drugs
| Hydrocodone-Acetaminophen | 14 | $88 | $6 |
| Oxycodone | 11 | $60 | $5 |
Money from drug and device companies
$17 in 2025
| 2025 | 1 | 1 | None | $17 |
| 2019 | 2 | 2 | None | $68 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer Healthcare Pharmaceuticals | Stivarga | $17 | 1 payment
|
See the published payment
| Bayer Healthcare Pharmaceuticals | Meals · 2025-06-17 | Stivarga | $17 |
See earlier years (2019)
2019: $68
| Medtronic USA | Nuvent | $39 | 1 payment
|
| Stryker | Entellus - Xpress Ent Dilation System | $29 | 1 payment
|
Professional record
- NPI
- 1285044669
- Licence
- CA A144953California A144953: Current · expires 2028-09-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Otolaryngology (207Y00000X)
- Mailing address
- 5800 Hollis St, Emeryville, CA, 94608
- NPI first listed
- 2014-05-06
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.